The proportion of patients in each group who experienced histologically confirmed recurrence of HCV at 120 weeks post randomization. 96 weeks [clinicaltrials_resource:7bfdedf94f5c8dd85aeeba18b823056d]
This group of patients will receive study drugs for the treatment of recurring (or returning) hepatitis C before they actually develop clinical symptoms of hepatitis C.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
The proportion of patients in each group who experienced histologically confirmed recurrence of HCV at 120 weeks post randomization. 96 weeks [clinicaltrials_resource:7bfdedf94f5c8dd85aeeba18b823056d]
This group of patients will receive study drugs for the treatment of recurring (or returning) hepatitis C before they actually develop clinical symptoms of hepatitis C.
Bio2RDF identifier
7bfdedf94f5c8dd85aeeba18b823056d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:7bfdedf94f5c8dd85aeeba18b823056d
measure [clinicaltrials_vocabulary:measure]
The proportion of patients in ...... 120 weeks post randomization.
time frame [clinicaltrials_vocabulary:time-frame]
description
This group of patients will re ...... nical symptoms of hepatitis C.
identifier
clinicaltrials_resource:7bfdedf94f5c8dd85aeeba18b823056d
title
The proportion of patients in ...... s post randomization. 96 weeks
@en
type
label
The proportion of patients in ...... dedf94f5c8dd85aeeba18b823056d]
@en